Current Approaches to Use Cyclodextrins and Mucoadhesive Polymers in Ocular Drug Delivery—A Mini-Review by Bíró, Tivadar & Aigner, Zoltán
Scientia 
Pharmaceutica
Review
Current Approaches to Use Cyclodextrins and
Mucoadhesive Polymers in Ocular Drug
Delivery—A Mini-Review
Tivadar Bíró and Zoltán Aigner *
University of Szeged, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6.
H-6720 Szeged, Hungary
* Correspondence: aigner@pharm.u-szeged.hu; Tel.: +36-62-545-577
Received: 28 May 2019; Accepted: 25 June 2019; Published: 28 June 2019


Abstract: Ocular drug delivery provides a challenging opportunity to develop optimal formulations
with proper therapeutic effects and acceptable patient compliance because there are many restricting
factors involved, such as complex anatomical structures, defensive mechanisms, rapid drainage,
and applicability issues. Fortunately, recent advances in the field mean that these problems can be
overcome through the formulation of innovative ophthalmic products. Through the addition of
solubility enhancer cyclodextrin derivatives and mucoadhesive polymers, the permeability of active
ingredients is improved, and retention time is increased in the ocular surface. Therefore, preferable
efficacy and bioavailability can be achieved. In this short review, the authors describe the theoretical
background, technological possibilities, and the current approaches in the field of ophthalmology.
Keywords: ocular drug delivery; pharmaceutical technology; ophthalmic formulation; cyclodextrin;
mucoadhesion; polymers
1. Introduction
Eyes are one of the most important organs of the human body and in the case of any dysfunction
in vision, serious drawbacks can appear in daily activities. Ocular drug delivery is a major challenge
in the pharmaceutical research and development field because of restrictions caused by many factors.
When considering patient-oriented therapy, patient compliance is a key factor, thus the mission of
many researchers is to find an optimal administration method that is self-applicable for the patients,
and to find the optimal formulation with accomplished therapeutic effect and zero irritation.
1.1. Anatomical and Physiological Perspectives
The complex anatomy of the eye limits the amount of therapy options for different diseases,
especially when deeper drug permeation is needed. The eye has two main parts; the anterior segment,
which includes the cornea, aqueous humor, iris, and lens, and the posterior segment, which includes
from the lens to the deeper tissues (vitreous humor, retina, sclera, optic nerve) (Figure 1). The cornea
consists of five layers; the lipophilic epithelium with tight junctions, Descemet’s membrane, the
hydrophilic stroma (which is the thickest part of the cornea), Bowman’s layer, and the lipophilic
endothelium [1–4]. When considering the optimal drug penetration through the cornea, a balance
between the hydrophilicity and lipophilicity of the drug and the delivery system is necessary. Due
to its complex anatomical structure, formed physiological barriers protect the eye from surrounding
exposures. The first barrier is built by the tear film and includes a lipid layer, mucins, and water.
It protects the cornea and conjunctiva. The composition of the corneal barrier was mentioned before.
It mainly restricts drug permeation to the anterior tissues. The conjunctival barrier consists of epithelial
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layers and connective tissue with blood and lymphatic vessels. The blood–aqueous barrier (BAB)
contains tight junctions of the capillary endothelium of the iris, and ciliary epithelium. It is mildly
permeable for low-weight molecules. The drug permeation is restricted from systemic circulation
to the posterior segment of the eye by the blood–retinal barrier (BRB) due to the tight junctions of
retinal pigment epithelium and the endothelial membrane of retinal blood vessels [5–7]. After any
stimulus reflex mechanisms, like lachrymal secretion and eye blinking, are induced, thus eliminating
the irritative agents in minutes from the eye surface. If the drug is passed through the cornea, the
opposite flow of aqueous humor also limits penetration to the posterior direction [8]. Therefore, these
mechanisms also limit the therapy by blocking drug permeation into the targeted tissues.
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1.2. Conventional Routes of Administration
Considering the above-mentioned defensive blockade, the process of ensuring the required therapy
is excessively difficult in ophthalmology. In clinical practice, there are invasive and non-invasive
methods for administration of the formulation to reach the targeted site (Table 1). Non-invasive routes,
also known as topical formulations, are mainly for reaching the anterior segment. The indications at
this site are cataract, glaucoma, dry eye, inflammatory diseases, trauma or surgery induced diseases,
injury, and tumor. Topical administration is the easiest and most commonly applied non-invasive
method which is self-applicable for the patient. Mostly eye-drops, semisolid formulations, inserts, and
contact lenses containing the active pharmaceutical ingredient (API) are used [1,9,10]. The requirements
are exact for these products. Sterile, isotonic, and microbiologically stable formulations must be
prepared with acceptable pH and viscosity. If any of the parameters differ from the optimal range,
defensive mechanisms are induced in the eye, therefore the expected efficacy would be much worse.
After application, the tear film barrier is the first blockade. For optimal drug permeation, sufficient
concentration of drug must present at the cornea. The second obstacle is the corneal barrier, where
firstly the drug meets the corneal epithelial multilayer. Because of the tight junction proteins between
the epithelial cells, penetration of hydrophilic molecules are restricted, and lipophilic drugs can
permeate transcellular by passive diffusion. The second part of the cornea is the stroma, which is a
hydrophilic environment, therefore the penetration of lipophilic drugs is restricted there. The lipophilic
endothelial monolayer is more transparent for macromolecules than the epithelium. The non-corneal
pathway is also known as conjunctival–scleral route, where the permeation mostly depends on the
molecular weight. Through the corneal and non-corneal pathway, the anterior tissues are partly
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reachable for the active ingredients. From the precorneal area (tear film), the applied formulation is
eliminated through the tear turnover and nasolacrimal drainage to the systemic circulation [11–13].
The invasive administration methods like intravitreal, subconjunctival injections, and inserts have
both advantages and limitations. With these methods, the target tissues are directly reachable, although
these invasive administrations are limited because of the required expertise, proper dosage, and
possible side-effects, like toxic reactions of the cornea. The subconjunctival application is less invasive,
although the elimination is decently fast through the conjunctival blood and lymphatic vessels.
Oral and intravenous administration are rather unfavored because of the presence of the BAB
and the first pass metabolism. To overcome the barrier, a high concentration of the drug needs to
be used, which is difficult because of the possible side effects and poor solubility of the most active
ingredients [14,15].
Table 1. Routes of administration to the eye with advantages and limitations.
Route of
Administration Advantages Limitations
Topical Patient-compliance, self-applicable,non-invasive, simple, no first-pass effect
Frequent administration needed, low
bioavailability, short contact time on the eye
surface, tear dilution
Subconjunctival Barely invasive, high efficacy, no firstpass effect
Fast clearance, expertise needed, not
self-applicable
Intravitreal High bioavailability, avoiding cornea,no first-pass effect
Critical dosing, very invasive method,
expertise needed, not patient compliant,
toxic side effects
Intravenous Avoiding cornea, less frequentapplication
Invasive, expertise needed, not targeted
exposure, large dose needed
Oral Patent compliant, non-invasive First pass effect, low ocular efficacy, nottargeted exposure, large dose needed
2. Novel Approaches in the Research of Ophthalmic Formulations
When considering the attributes of physiological obstacles of administration routes, an innovative
solution is required, one that is acceptable in terms of patient compliance and efficient therapy.
A topically self-administrable formulation would be optimal, with enhanced drug permeability into
the anterior/posterior tissues and increased residence time on the surface of the eye. Enticing results
are published on the impact of complex of drug-cyclodextrin derivatives, mucoadhesive polymers,
and nanotechnology. This short review on recent ocular drug delivery approaches summarizes these
innovations from recent years.
2.1. Cyclodextrins
To reach optimal penetration, the API needs to be dissolved in lachrymal fluid and pass the
tear film barrier. If the concentration of API is going to be optimal near the corneal epithelium,
a steady amount needs to be ensured for optimal permeation [16]. A major challenge is presented
by the fact that the applied APIs in ophthalmology are mostly lipophilic molecules, with low water
solubility. Application of solubility enhancer additives, like cyclodextrins (CD) could be the first step
for the optimization of eye drop formulations. CDs are cyclic oligosaccharides with α-(1,4) linked
α-D-glucopyranose units. In nature, three types are formed by bacterial digestion of starch; α-CD
with 6, β-CD with 7, and γ-CD with 8 glucopyranose units. The external surface of these molecules is
hydrophilic due to the orientation of hydroxyl groups, which form hydrogen bonds with surrounding
water molecules. Inside the cavity of CDs, the environment is hydrophobic, therefore an inclusion
complex can be formed with lipophilic agents by hydrogen bonds, van der Waals, and charge-transfer
interactions. In aqueous solution dynamic equilibrium is created between the free CD and drug
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molecules and the complex. After application on the eye surface, only the free lipophilic molecule can
permeate through the cornea, the hydrophilic CD remains and is eventually eliminated through the
nasolacrimal pathway (Figure 2).Sci. Pharm. 2019, 87, x FOR PEER REVIEW 4 of 11 
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Figure 2. Schematic figure about the cyclodextrin drug permeability enhancer attributes.
With the formation of inclusion complexes, the APIs are dissolved in the tear and concentrated
near the cornea epithelium. Low or unnecessarily high amounts of CD restrict the permeation of
drug, thus the CD concentration needs to be optimized in the formulation [16–21]. To investigate the
formation of the inclusion complex in solution, the phase solubility test is a well-kno n ethod, which
has been described previously by Higuchi and Con ors. The stability constant of the co (KS) is
calculable from the slope f p ase solubility diagram using Higuchi–Connors equation (Equation (1)):
Ks = Slope/{Intercept (1 lope)} (1)
The intensity of binding forces between the I and CD molecules can be established by the
stability constant [22,23]. A phase–solubility diagram is shown on Figure 3, which was published
before by our research group [24].
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Figure 3. Phase–solubility d agram of prednisol ne (PR)- roxypropyl-β-cyclodextrin (HPBCD)
and PR-hy roxypropyl-γ-c clodextrin (HPGCD) inclusion c lexes. The solubility of PR increased
linearly by increasing the concentration of cyclodextrins (CDs). The curve is AL type, thus inclusion
complexes with 1:1 molecular ratio are formed in the case of HPGCD and HPBCD [24].
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In the solid state, the formation of drug–CD inclusion complexes can be investigated by
differential scanning calorimetry (DSC), Fourier-transformed infrared spectroscopy (FTIR), X-Ray
powder diffraction (XRPD) and C13-NMR methods. Considering the changes in physicochemical
attributes, crystallization, and the IR spectrum, the formation of complexes can be assumed [25–28].
CD derivatives have been developed with more favorable attributes like increased solubility,
stability, and less toxicity. In ophthalmic formulations the hydroxypropyl-β-and γ-cyclodextrin
and sulfobuthylaether-β-cyclodextrin are the most commonly applied derivatives, which are also
official in European Pharmacopoeia. Studies on rabbit corneal epithelial cell-line showed non-toxic
attributes after application of these types of CDs [29–32]. Recent approaches are shown on Table 2.,
where CDs are applied in ophthalmic formulations.
Table 2. Recent approaches to use CDs in ophthalmic formulations.
API CD Derivative Formulation Reference
Flurbiprofen HPBCD eye drop [33]
Nepafenac HPBCDHPGCD eye drop [34]
Amlodipine HPBCDSBEBCD eye drop [35]
Dexamethasone acetate HPBCDHPGCD eye drop [36]
Cyclosporine HPBCD insert [37]
2.2. Mucoadhesion
Application of polymers for prolonged ocular drug delivery is a common strategy. When the
viscosity is increased, necessarily not to a high level, the residence time of the eye drop on the surface
of the eye is prolonged without any side-effect, such as visual disorder or irritation. Mucoadhesive
polymers are especially useful, because of the possible adhesion due to the interaction of polymer chains
and the mucin layer of the tear film. It is defined as bioadhesion if the polymer chains are attached to the
biological surface. Several theories are associated with the mechanisms of mucoadhesion. The wetting
theory describes the effect of drop spreadability and wettability on the eye surface. According to the
electrosatic theory, electron transfer is the mechanism of mucoadhesion. Adsorption theory is about
primary and secondary chemical bonds between the polymer and mucus. In the case of high molecular
weight polymers, the diffusion of polymer chains and glycoproteins of mucus can interpenetrate
into each other creating an intermolecular net and mucoadhesion. This mechanism is also known as
mechanical theory (Figure 4) [38–42].
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interpenetration f polymer chains After application, the polymer chains penetrate during
the spreading rop on the ocular surface.
The most commonly used mucoadhesive polymers are carbomers, alginates, methylcellulose,
hydroxypropylmethylcellulose, hydroxyethylcellulose, chitosan, thiolated polymers and hyaluronic
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acid. Biopolymers like hyaluronic acid are favorable in ophthalmic formulations, because of the
biocompatible, non-toxic and biodegradable attributes [40,43,44].
2.3. Cyclodextrins and Mucoadhesive Polymers as Ophthalmic Drug Delivery Systems
Patient-compliance and effective therapy is desired, where the medicine is self-applicable, safe,
and economical. Topical eye drop formulations would be optimal if they matched all previously
mentioned requirements. Nowadays, several research groups have published articles about approaches
for improved ocular drug delivery systems, where the API was dissolved in the aqueous solvent by CD
complex formation, and the residence time was increased by mucoadhesive polymers, and therefore
expected to have higher therapeutic efficacy [19,43,45].
Our research group has developed a promising formulation, where the prednisolone(PR)–CD
complex was dissolved in aqueous solution containing zinc-hyaluronate and zinc-gluconate. With
the addition of zinc-hyaluronate–zinc-gluconate system (ZnHA–ZnGlu), the antimicrobial stability
was ensured during storage, application, and due to mucoadhesive attributes, increased residence
time is expected on the eye surface. The osmolality and pH were set to physiological parameters by
the sodium–chloride and borate buffer. Optimal PR diffusion was investigated in vitro using dialysis
cellulose membrane. Mucoadhesive properties were tested by tensile test on mucin impregnated
surface. All of the samples show that the mucoadhesivity, formulations with ZnHA–ZnGlu have
significantly higher adhesive force values (Figure 5). [24].
Sci. Pharm. 2019, 87, x FOR PEER REVIEW 6 of 11 
 
The most commonly used mucoadhesive polymers are carbomers, alginates, methylcellulose, 
hydroxypropylmethylcellulose, hydroxyethylcellulose, chitosan, thiolated polymers and hyaluronic 
acid. Biopolymers like hyaluronic acid are favorable in ophthalmic formulations, because of the 
biocompatible, non-toxic and biodegradable attributes [40,43,44]. 
2.3. Cyclodextrins and Mucoadhesive Polymers as Ophthalmic Drug Delivery Systems 
Patient-compliance an  effective therapy is desired, where the medicin  is self-applicable, safe, 
and economical. Topical ye drop formulations would be optimal if they matched all previously 
mentioned requirements. Nowadays, several research groups have published articles about 
approaches for improved ocular drug delivery systems, where the API was dissolved in the aqueous 
solvent by CD complex formation, and the residence time was increased by mucoadhesive polymers, 
and therefore expected to have higher therapeutic efficacy [19,43,45]. 
Our research group has developed a promising formulation, where the prednisolone(PR)–CD 
complex was dissolved in aqueous solution containing zinc-hyaluro ate and zinc-gluconate. With 
the addition of zinc-hyaluronate–zinc-gluconate syste  (ZnHA–ZnGlu), the antimicrobial stability 
was ensured during storage, application, and due to mucoadhesive attributes, increased residence 
time is expected on the eye surface. The osmolality and pH were set to physiological parameters by 
the sodium–chloride and borate buffer. Optimal PR diffusion was investigated in vitro using dialysis 
cellulose membrane. Mucoadhesive properties were tested by tensile test on mucin impregnated 
surface. All of the samples show that the mucoadhesi ity, formulations with ZnHA–ZnGlu have 
significantly higher adhesive force values (Figure 5). [24  
 
Figure 5. Results of tensile test with (white columns) and without (black columns) mucin. (1, with 
HPBCD; 2, with HPGCD; 3, with HPBCD and ZnHA–ZnGlu; 4, with HPGCD and ZnHA–ZnGlu) [24] 
(*** p ≤ 0.001). 
An innovative approach was published by Budai-Szűcs et al., where PR was incorporated into 
cyclodextrin-modified thiolated poly(aspartic acid) in aqueous in situ gelling solution. The complex 
formation was investigated by the XRPD method, as were the physicochemical attributes, rheology, 
and drug diffusion. In the drug diffusion study PR suspension was used as reference. The drug 
diffusion was tested over 24 h (Figure 6). In the case of the unbound PR cyclodextrin complex 
containing thiolated polymer gel, the diffusion rate was similar to PR suspension, due to the 
increased solubility and the prolonged effect of the polymer. In the formulation where the CD was 
covalently bound to the thiolated polymer, the drug diffusion was slower and dependent on the 
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Figure 5. Results of tensile test wi h (white columns) ithout (black columns) mucin. (1, with
HPBCD; 2, with HPGCD; 3, with HPBCD and ZnHA– l ; 4, with HPGCD and ZnHA–ZnGlu) [24]
(*** p ≤ 0.001).
An innovative approach was published by Budai-Szu˝cs et al., where PR was incorporated into
cyclodextrin-modified thiolated poly(aspartic acid) in aqueous in situ gelling solution. The complex
formation was investigated by the XRPD method, as were the physicochemical attributes, rheology, and
drug diffusion. In the drug diffusion study PR suspension was sed as reference. The drug diffusion
was tested over 24 h (Figure 6). In the case of the unbound PR cyclodextrin complex containing
thiolated polymer gel, the diffusion rate was similar to PR suspension, due to the increased solubility
and the prolonged effect of the polymer. In the formulation where the CD was covalently bound to
the thiolated polymer, the drug diffusion was slower and dependent on the dissociation of PR from
the CD complex and the inhibition of the polymer matrix. With the combination of the two type of
formulations, an intermediate diffusion rate was observed. In this case the free PR–CD complexes
caused a rapid biological effect, meanwhile the bound complexes prolong the drug release on the eye
surface, therefore a less frequent application is needed to reach the target therapy [46].
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Figure 6. Drug release from the formulations containing prednisolone (PR). Cumulative mean values
and standard deviations (SD) n = 3; PR: prednisolone, PASP-CEA: Thiolated poly(aspartic acid),
MABCD: 6-monodeoxy-6-monoamino-beta-cyclodextrin hydrochloride [46].
Nanda et al. developed amlodipine containing mucoadhesive films through the addition of
hydroxypropyl methylcellulose (HPMC) and CD derivatives (β-CD, HPBCD, sulfobuthylaether-β-
cyclodextrin) using casting and solvent-evaporation methods. The authors investigated the swelling
and erosive attributes, morphology, inclusion complex formation by DSC, FTIR and XRPD, in vitro and
ex vivo diffusion of drug and anti-inflammatory effect on carrageenan induced rabbit model. As the
result of the ex vivo permeations s udy shows, the applied CDs increased the permeability of drug on
the excised sheep cornea, meanwhile the flux was dependent on the binding constants of the differ nt
CDs (Figure 7) [35].
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Shelley et al. published promising results about in situ gelling, nepafenac-HPBCD complex,
sodium alginate containing ophthalmic formulation. Ex vivo permeability of API was tested using
excised porcine cornea for 24 hours. The results showed that, the drug permeation from in situ gelling
formulations was significantly higher compared with the official suspension formulation, Nevanac®,
which was caused by the permeability enhancer effect of HPBCD. The highest permeation was observed
in the case of composition F15 due to the low viscosity (Figure 8). This article also confirms the
favorable effect of adding cyclodextrin and mucoadhesive polymers into the developed ocular drug
delivery system [47].
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